The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep
Often characterized by involuntary motor or vocal tics, Tourette syndrome typically appears in childhood and affects up to ...
Clinical Advisor1d
Novel Dopamine-1 Receptor Antagonist Shows Promise for Tourette Syndrome
By blocking dopamine-1 receptors, ecopipam is expected to reduce the repetitive and compulsive behaviors seen in Tourette syndrome.
Clinical Trials Arena on MSN16d
Emalex eyes FDA approval for Tourette syndrome therapy after Phase III success
The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients.
People on MSN11d
Baylen Dupree Contemplates 'Life-Changing' Surgery to Treat Her Tourette Syndrome (Exclusive)
Baylen Dupree is saying “hell no” to a potential treatment for her Tourette syndrome. In PEOPLE's exclusive look at the ...
Medscape8d
Diagnosis and Management of Tourette Syndrome: Practical Aspects
Tourette syndrome (TS) is clinically significant because it is much more common than previously thought, is easily misdiagnosed, and is often associated with significant comorbidity ...
Wake Forest University School of Medicine recognized by Tourette Association of America Center of Excellence
Wake Forest University School of Medicine and Atrium Health Wake Forest Baptist Medical Center have been recognized by the ...